| Accession |
PRJCA010724 |
| Title |
An international multicenter Phase I clinical study of SR-A1811 in patients with advanced solid tumors with HER2 expression or mutation |
| Relevance |
Medical |
| Data types |
clinical data\Metabolic data\biomarker\image data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate SR-A1811 in patients with advanced solid tumors with HER2 expression or mutation Safety and tolerability to determine the recommended dose for the Phase II clinical study of SHR-A1811 (RP2D) |
| Sample scope |
Multiisolate |
| Release date |
2022-07-22 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Jiangsu Hengrui Pharmaceutical Co. LTD
|
|
SHR-A1811-101
|
|
|
|
| Submitter |
weiqing ge
weiqing
ge (weiqing.ge@hengrui.com)
|
| Organization |
Jiangsu Hengrui pharmaceutical Co.LTD |
| Submission date |
2022-07-22 |
